Alaunos Therapeutics, Inc. (WEK.MU)
- Previous Close
0.9950 - Open
0.9950 - Bid --
- Ask --
- Day's Range
0.9950 - 0.9950 - 52 Week Range
0.9950 - 14.9250 - Volume
430 - Avg. Volume
0 - Market Cap (intraday)
15.932M - Beta (5Y Monthly) -0.36
- PE Ratio (TTM)
-- - EPS (TTM)
-5.7300 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
www.alaunos.comRecent News: WEK.MU
Performance Overview: WEK.MU
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: WEK.MU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: WEK.MU
Valuation Measures
Market Cap
18.46M
Enterprise Value
12.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
2.56k
Enterprise Value/EBITDA
-0.41
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.66%
Return on Equity (ttm)
-156.66%
Revenue (ttm)
5k
Net Income Avi to Common (ttm)
-35.14M
Diluted EPS (ttm)
-5.7300
Balance Sheet and Cash Flow
Total Cash (mrq)
6.06M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.1M